文章：

恶性胸膜间皮瘤：从病理生理学到创新性可操作靶点

Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets

原文发布日期：30 March 2025

DOI: 10.3390/cancers17071160

类型: Article

开放获取: 是

英文摘要：

Background: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6–18 months. Objectives: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy. Methods: This review examines advancements in understanding PM’s genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets. Results: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.

摘要翻译： 

背景：胸膜间皮瘤（PM）是一种罕见且高度侵袭性的癌症，起源于间皮层，主要与石棉暴露、遗传易感性和特定基因突变相关。尽管目前已有化疗、抗血管生成治疗以及近年来的免疫疗法等多种治疗手段，但其预后依然不佳，中位生存期仅为6至18个月。目的：对新治疗策略的迫切需求推动了对分子靶点及精准医疗方法的研究。目前，已识别出多个潜在治疗靶点，新兴的临床试验也显示出一定的临床疗效。方法：本综述探讨了在理解胸膜间皮瘤的遗传与表观遗传特征、信号通路以及有前景的治疗靶点方面的研究进展。结果：我们还讨论了近期临床试验的结果及其对未来治疗模式的潜在影响。

原文链接：

Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets